Trial Profile
A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 11 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2023 Planned End Date changed from 1 Dec 2024 to 6 Mar 2025.
- 13 Mar 2023 Planned primary completion date changed from 1 Dec 2023 to 6 Mar 2024.